Bli medlem
Bli medlem

Du är här

2016-10-20

Hansa Medical: Hansa Medical proposes a directed share issue

· The board of directors of Hansa Medical AB (publ) ("Hansa Medical"
or the "Company") proposes a directed share issue of approximately
SEK 185 million.

· The subscription price for the issue is proposed to be SEK 70 per
share.

· The issue is directed to selected international specialist
investors including HBM Healthcare Investments, Sectoral Asset
Management, Sphera Funds Management and Aescap, as well as Swedish
institutional and strategic investors including Carnegie Asset
Management,

AFA Insurance, KK-stiftelsen, Thomas Olausson and Unionen.
· Shareholders representing approximately 45 per cent of the shares
and votes of Hansa Medical have undertaken to vote in favour of the
issue at the extraordinary general meeting.

· The board of directors has today announced a notice for an
extraordinary general meeting to resolve on the share issue (for full
details, see separate press release with notice for an extraordinary
meeting).

NOT FOR DISTRIBUTION OR PUBLIC RELEASE, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER
JURISDICTION IN WHICH SUCH MEASURES WOULD BE IN VIOLATION OF
APPLICABLE REGULATIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN
OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY
SECURITIES IN HANSA MEDICAL IN ANY JURISDICTION.

Background and reasons
In order to secure continued value creation for the Company of its
projects, the board of directors proposes a directed issue of new
shares. The issue proceeds will primarily be invested in the
development of the drug candidate IdeS up to an application for
market authorization of IdeS in kidney transplantation. The issue
also enables the Company to secure a broadened investor base with an
increase in international and Swedish institutional investors, which
supplements the Company's current strong shareholder base. All in
all, the issue enables Hansa Medical to continue to grow into a
pharmaceutical company with proprietary products on the market.

"The proposed directed issue is expected to secure the funds necessary
to develop our lead candidate IdeS up to the filing for marketing
authorization of IdeS in treatment of kidney transplantation", says
Göran Arvidson, CEO of Hansa Medical.

"Our cash position, including existing cash and cash equivalents, will
also allow us to investigate the safety and efficacy of IdeS through
several Phase II clinical trials in a number of prioritized
indications. These include the serious autoimmune diseases thrombotic
thrombocytopenic purpura (TTP), anti-GBM disease and Guillain-Barré
syndrome (GBS), as well as the transplant indications
antibody-mediated rejection (AMR) post kidney transplantation and
blood group incompatible (ABOi) kidney transplantation. Our long term
vision is to establish IdeS as a therapy for rapid and effective
antibody inactivation in a wide range of diseases with significant
unmet medical need."

The issue
The board of directors has resolved to propose the extraordinary
general meeting to resolve on a directed share issue of not more than
2,642,857 shares. The subscription price for the issue corresponds to
SEK 70 per share, which, in total, will provide the Company with
approximately SEK 185 million before issue costs. The subscription
price for the issue has been determined through a so-called private
placement procedure. The directed issue will be fully subscribed by a
number of selected international specialist investors including HBM
Healthcare Investments, Sectoral Asset Management, Sphera Funds
Management and Aescap, as well as Swedish institutional and strategic
investors including Carnegie Asset Management, AFA Insurance,
KK-stiftelsen, Thomas Olausson and Unionen, in accordance with
separate agreements.

Shareholders representing approximately 45 per cent of the shares and
votes in Hansa Medical, including Nexttobe AB, Gladiator and
Farstorps Gård AB, have undertaken to vote in favour of the issue at
the extraordinary general meeting.

The reasons for the deviation from the shareholders' pre-emption
rights are that the Company shall, in a timely manner, be able to
secure the Company's capital need for the operations, as well as to
broaden the ownership structure of the Company with strategic and
institutional investors, which is also supported by the Company's
largest shareholders, who are not participating in the issue. Through
the issue, the share capital will increase with SEK 2,642,857 to SEK
35,054,860, which entails a dilution effect of approximately 8 per
cent of both the number of shares and votes.

The extraordinary general meeting will be held on 21 November 2016 at
the Company's offices on Scheelevägen 22 in Lund.

Advisors
Hansa Medical has, in connection with the transaction, engaged Zonda
Partners as advisor, Carnegie Investment Bank as financial advisor
and Advokatfirman Vinge as legal advisor.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
This information is such information that Hansa Medical AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of
the contact person set out above, at 8:30 am CEST on 20 October 2016.

_____________________________________________

Important information

The release, announcement or distribution of this press release may,
in certain jurisdictions, be subject to restrictions. The recipient
of this press release is responsible for using the information in
this press release in accordance with applicable law in each
jurisdiction. This press release does not constitute an offer, or a
solicitation of any offer, to buy or subscribe for any securities in
Hansa Medical in any jurisdiction.

This press release is not a prospectus for the purposes of Directive
2003/71/EC as amended through Directive 2010/73/EU. Hansa Medical has
not authorized any offer to the public of shares or rights in any
member state of the EEA and no prospectus or other offering document
has been or will be prepared in connection with the directed share
issue.

About IdeS
IdeS, a unique molecule with a novel mechanism, is an enzyme that
specifically cleaves human IgG antibodies. IdeS has been evaluated in
a Phase I study in healthy subjects and in a Phase II study in
sensitized patients awaiting kidney transplantation demonstrating
that IdeS is highly effective in reducing anti-HLA antibodies to
levels acceptable for transplantation with a favorable safety
profile. The efficacy and safety of IdeS in transplantation are
currently investigated in three on-going Phase II studies in
sensitized kidney patients in Sweden and the US. In addition to
transplantation, IdeS has potential applications in a variety of rare
autoimmune diseases and currently, the efficacy and safety of IdeS is
investigated in a Phase II study in acquired Thrombotic
Thrombocytopenic Purpura.

About Hansa Medical AB (publ)
Hansa Medical is a biopharmaceutical company focusing on novel
immunomodulatory enzymes. The lead project IdeS is an
antibody-degrading enzyme in clinical development, with potential use
in transplantation, rare autoimmune diseases and oncology. Additional
projects focus on development of new antibody modulating enzymes, as
well as HBP, a diagnostic biomarker for prediction of severe sepsis
at emergency departments that is already introduced on the market.
The company is based in Lund, Sweden. Hansa Medical's share (ticker:
HMED) is listed on Nasdaq Stockholm.

-----------------------------------------------------------
http://news.cision.com/hansa-medical/r/hansa-medical-proposes-a-directed...
http://mb.cision.com/Main/1219/2104891/577512.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.